Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management.
Couture et al. perform an interesting meta-analysis of 5 previously reported, placebo-controlled epoetin alfa studies in anemic cancer patients on chemotherapy. Their conclusions are simple and intuitive: previous blood transfusion […]
A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
An important trial by Schwartzberg et al. has recently been published in The Oncologist. In prospective manner, this trial tested the two erythropoietin preparations commonly used in the US, epoetin […]
Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation.
The use of rFVIIa in conditions associated with disseminated intravascular coagulation (DIC) has always been an area of concern in view of the theoretical possibility of enhancing thrombotic complications. However, […]
Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial.
A nice demonstration again in a placebo controlled trial that recombinant EPO is safe and effective in anemic cancer patients on chemorx. The three times weekly dose is more commonly […]
Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy – results of a randomized trial.
This positive study demonstrated that epoetin patients did better than no epoetin control patients in a relapsed lymphoma, autologous stem cell transplant setting. Epoetin has been shown not to be […]
Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.
A nicely done placebo controlled trial of darbepoetin in anemic hematologic malignancy patients demonstrating darbepoetin’s efficacy and safety. – David H. Henry
Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production.
This is an important EPO trial in hematologic malignancy patients for two reasons. It demonstrates that lower EPO levels predict response… an observation not reproduced in solid tumor patients but […]
Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
This is a well done study of anemic cancer patients on cisplatin chemotherapy that documents nicely that the best predictor of an ultimate good response to epoetin is an early […]
Recombinant human erythropoietin in pediatric oncology: a review.
Important to attempt review, but too much variability in studies to form meaningful conclusion. – Patricia Ford
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
Excellent design. – Patricia Ford
Exposure to allogeneic plasma and risk of postoperative pneumonia and/or wound infection in coronary artery bypass graft surgery.
The study is very important with regard to the question of whether plasma-poor RBCs cause less immunosuppression than RBC units containing more or less plasma (e.g., whole blood). It can […]
High intensity focused ultrasound: A method of hemostasis.
This inovative work bears watching. Potential applications include minimally invasive, i.e., laparoscopic, approaches to control of traumatic liver injury. – R. K. Spence.